Optimal timing of blood samplings to detect GH inhibition during oral glucose tolerance test
Background In patients with suspected acromegaly, evaluation of IGF-I is recommended as first-line test, while the assessment of GH-nadir during oral glucose tolerance test (OGTT) is advised as confirmatory test. The procedure of this test generally involves GH measurement every 30 min (30’) from ba...
Saved in:
| Published in | Journal of endocrinological investigation Vol. 45; no. 5; pp. 981 - 987 |
|---|---|
| Main Authors | , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Cham
Springer International Publishing
01.05.2022
Springer Nature B.V |
| Subjects | |
| Online Access | Get full text |
| ISSN | 1720-8386 0391-4097 1720-8386 |
| DOI | 10.1007/s40618-021-01731-0 |
Cover
| Abstract | Background
In patients with suspected acromegaly, evaluation of IGF-I is recommended as first-line test, while the assessment of GH-nadir during oral glucose tolerance test (OGTT) is advised as confirmatory test. The procedure of this test generally involves GH measurement every 30 min (30’) from baseline to +120’ or +180’. However, the optimal timing of samplings for the distinction between patients with or without active acromegaly is still a matter of debate.
Methods
Sixty-seven healthy subjects and 46 acromegalic patients who achieved documented and persistent long-term cure were enrolled. A greedy algorithm was used to identify the minimal subset of time-points that sufficed to correctly detect GH suppression.
Results
The sampling at 90’ was the one in which a GH level < 1 μg/L was most frequently achieved (i.e., in 91.3% of cured acromegalic patients and in 91.0% of healthy subjects). Considering the whole cohort, the best combination of 2 time-points was +90’ and +150’ and achieved 95.6% accuracy; the best combination of 3 time-points was +60’, +90’ and +150’ and achieved 99.1% accuracy. The minimal subset of GH determinations that demonstrated perfect accuracy (100%) needed the inclusion of 4 time-points, namely +60’, +90’, +120’ and +150’.
Conclusion
A subset of 4 time-points (60’ – 90’ – 120’ – 150’) was identified as the most relevant to detect GH suppression at OGTT, with a perfect classification of 100% of subjects. This supports the possibility to restrict the blood samplings to these time-points when assessing disease cure, with possible advantages in terms of saving time and lowering costs. |
|---|---|
| AbstractList | In patients with suspected acromegaly, evaluation of IGF-I is recommended as first-line test, while the assessment of GH-nadir during oral glucose tolerance test (OGTT) is advised as confirmatory test. The procedure of this test generally involves GH measurement every 30 min (30') from baseline to +120' or +180'. However, the optimal timing of samplings for the distinction between patients with or without active acromegaly is still a matter of debate.
Sixty-seven healthy subjects and 46 acromegalic patients who achieved documented and persistent long-term cure were enrolled. A greedy algorithm was used to identify the minimal subset of time-points that sufficed to correctly detect GH suppression.
The sampling at 90' was the one in which a GH level < 1 μg/L was most frequently achieved (i.e., in 91.3% of cured acromegalic patients and in 91.0% of healthy subjects). Considering the whole cohort, the best combination of 2 time-points was +90' and +150' and achieved 95.6% accuracy; the best combination of 3 time-points was +60', +90' and +150' and achieved 99.1% accuracy. The minimal subset of GH determinations that demonstrated perfect accuracy (100%) needed the inclusion of 4 time-points, namely +60', +90', +120' and +150'.
A subset of 4 time-points (60' - 90' - 120' - 150') was identified as the most relevant to detect GH suppression at OGTT, with a perfect classification of 100% of subjects. This supports the possibility to restrict the blood samplings to these time-points when assessing disease cure, with possible advantages in terms of saving time and lowering costs. In patients with suspected acromegaly, evaluation of IGF-I is recommended as first-line test, while the assessment of GH-nadir during oral glucose tolerance test (OGTT) is advised as confirmatory test. The procedure of this test generally involves GH measurement every 30 min (30') from baseline to +120' or +180'. However, the optimal timing of samplings for the distinction between patients with or without active acromegaly is still a matter of debate.BACKGROUNDIn patients with suspected acromegaly, evaluation of IGF-I is recommended as first-line test, while the assessment of GH-nadir during oral glucose tolerance test (OGTT) is advised as confirmatory test. The procedure of this test generally involves GH measurement every 30 min (30') from baseline to +120' or +180'. However, the optimal timing of samplings for the distinction between patients with or without active acromegaly is still a matter of debate.Sixty-seven healthy subjects and 46 acromegalic patients who achieved documented and persistent long-term cure were enrolled. A greedy algorithm was used to identify the minimal subset of time-points that sufficed to correctly detect GH suppression.METHODSSixty-seven healthy subjects and 46 acromegalic patients who achieved documented and persistent long-term cure were enrolled. A greedy algorithm was used to identify the minimal subset of time-points that sufficed to correctly detect GH suppression.The sampling at 90' was the one in which a GH level < 1 μg/L was most frequently achieved (i.e., in 91.3% of cured acromegalic patients and in 91.0% of healthy subjects). Considering the whole cohort, the best combination of 2 time-points was +90' and +150' and achieved 95.6% accuracy; the best combination of 3 time-points was +60', +90' and +150' and achieved 99.1% accuracy. The minimal subset of GH determinations that demonstrated perfect accuracy (100%) needed the inclusion of 4 time-points, namely +60', +90', +120' and +150'.RESULTSThe sampling at 90' was the one in which a GH level < 1 μg/L was most frequently achieved (i.e., in 91.3% of cured acromegalic patients and in 91.0% of healthy subjects). Considering the whole cohort, the best combination of 2 time-points was +90' and +150' and achieved 95.6% accuracy; the best combination of 3 time-points was +60', +90' and +150' and achieved 99.1% accuracy. The minimal subset of GH determinations that demonstrated perfect accuracy (100%) needed the inclusion of 4 time-points, namely +60', +90', +120' and +150'.A subset of 4 time-points (60' - 90' - 120' - 150') was identified as the most relevant to detect GH suppression at OGTT, with a perfect classification of 100% of subjects. This supports the possibility to restrict the blood samplings to these time-points when assessing disease cure, with possible advantages in terms of saving time and lowering costs.CONCLUSIONA subset of 4 time-points (60' - 90' - 120' - 150') was identified as the most relevant to detect GH suppression at OGTT, with a perfect classification of 100% of subjects. This supports the possibility to restrict the blood samplings to these time-points when assessing disease cure, with possible advantages in terms of saving time and lowering costs. BackgroundIn patients with suspected acromegaly, evaluation of IGF-I is recommended as first-line test, while the assessment of GH-nadir during oral glucose tolerance test (OGTT) is advised as confirmatory test. The procedure of this test generally involves GH measurement every 30 min (30’) from baseline to +120’ or +180’. However, the optimal timing of samplings for the distinction between patients with or without active acromegaly is still a matter of debate.MethodsSixty-seven healthy subjects and 46 acromegalic patients who achieved documented and persistent long-term cure were enrolled. A greedy algorithm was used to identify the minimal subset of time-points that sufficed to correctly detect GH suppression.ResultsThe sampling at 90’ was the one in which a GH level < 1 μg/L was most frequently achieved (i.e., in 91.3% of cured acromegalic patients and in 91.0% of healthy subjects). Considering the whole cohort, the best combination of 2 time-points was +90’ and +150’ and achieved 95.6% accuracy; the best combination of 3 time-points was +60’, +90’ and +150’ and achieved 99.1% accuracy. The minimal subset of GH determinations that demonstrated perfect accuracy (100%) needed the inclusion of 4 time-points, namely +60’, +90’, +120’ and +150’.ConclusionA subset of 4 time-points (60’ – 90’ – 120’ – 150’) was identified as the most relevant to detect GH suppression at OGTT, with a perfect classification of 100% of subjects. This supports the possibility to restrict the blood samplings to these time-points when assessing disease cure, with possible advantages in terms of saving time and lowering costs. Background In patients with suspected acromegaly, evaluation of IGF-I is recommended as first-line test, while the assessment of GH-nadir during oral glucose tolerance test (OGTT) is advised as confirmatory test. The procedure of this test generally involves GH measurement every 30 min (30’) from baseline to +120’ or +180’. However, the optimal timing of samplings for the distinction between patients with or without active acromegaly is still a matter of debate. Methods Sixty-seven healthy subjects and 46 acromegalic patients who achieved documented and persistent long-term cure were enrolled. A greedy algorithm was used to identify the minimal subset of time-points that sufficed to correctly detect GH suppression. Results The sampling at 90’ was the one in which a GH level < 1 μg/L was most frequently achieved (i.e., in 91.3% of cured acromegalic patients and in 91.0% of healthy subjects). Considering the whole cohort, the best combination of 2 time-points was +90’ and +150’ and achieved 95.6% accuracy; the best combination of 3 time-points was +60’, +90’ and +150’ and achieved 99.1% accuracy. The minimal subset of GH determinations that demonstrated perfect accuracy (100%) needed the inclusion of 4 time-points, namely +60’, +90’, +120’ and +150’. Conclusion A subset of 4 time-points (60’ – 90’ – 120’ – 150’) was identified as the most relevant to detect GH suppression at OGTT, with a perfect classification of 100% of subjects. This supports the possibility to restrict the blood samplings to these time-points when assessing disease cure, with possible advantages in terms of saving time and lowering costs. |
| Author | Varaldo, E. Bioletto, F. Gasco, V. Ghigo, E. Prencipe, N. Berton, A. M. Grottoli, S. Bona, C. |
| Author_xml | – sequence: 1 givenname: F. orcidid: 0000-0001-7550-7023 surname: Bioletto fullname: Bioletto, F. email: fabio.bioletto@unito.it organization: Endocrinology, Diabetology and Metabolism, Department of Medical Sciences, University of Turin – sequence: 2 givenname: N. surname: Prencipe fullname: Prencipe, N. organization: Endocrinology, Diabetology and Metabolism, Department of Medical Sciences, University of Turin – sequence: 3 givenname: A. M. surname: Berton fullname: Berton, A. M. organization: Endocrinology, Diabetology and Metabolism, Department of Medical Sciences, University of Turin – sequence: 4 givenname: C. surname: Bona fullname: Bona, C. organization: Endocrinology, Diabetology and Metabolism, Department of Medical Sciences, University of Turin – sequence: 5 givenname: E. surname: Varaldo fullname: Varaldo, E. organization: Endocrinology, Diabetology and Metabolism, Department of Medical Sciences, University of Turin – sequence: 6 givenname: V. surname: Gasco fullname: Gasco, V. organization: Endocrinology, Diabetology and Metabolism, Department of Medical Sciences, University of Turin – sequence: 7 givenname: E. surname: Ghigo fullname: Ghigo, E. organization: Endocrinology, Diabetology and Metabolism, Department of Medical Sciences, University of Turin – sequence: 8 givenname: S. surname: Grottoli fullname: Grottoli, S. organization: Endocrinology, Diabetology and Metabolism, Department of Medical Sciences, University of Turin |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/35098493$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kU1PHSEUhomx8fsPuDAk3XQzFoYZYJbGtGpi4qbdmRAGzlUMdxiBWfTf91yvrcaFGzghzwOH9xyS3SlNQMgpZ-ecMfW9dExy3bCWN4wrgesOOeCqZY0WWu6-q_fJYSlPjAkltNoj-6Jng-4GcUDu7-Ya1jZSXMP0QNOKjjElT4tdzxFPCq2JeqjgKr26pmF6DGOoIU3UL_nFyGg_xMWlAshGyHZyWEGpx-TLysYCJ6_7Efn988evy-vm9u7q5vLitnFC9bXxctRt763VTo6jGpUHcAqweyFW3Om-H1wHgsth9MoBeMalFNJrBRqlQRyRb9t755yeF3zYrENxEKOdIC3FtLLtWvz9sEG_fkCf0pIn7A6pbmC87zuF1NkrtYxr8GbOmFH-Y_7lhkC7BVxOpWRY_Uc4M5vhmO1wDA7HvAzHMJT0B8mFajdZ1mxD_FwVW7XMm9Ahv7X9ifUXFpmjHw |
| CitedBy_id | crossref_primary_10_1007_s40618_024_02396_1 |
| Cites_doi | 10.1530/EJE-08-0284 10.1210/jc.2009-2670 10.1007/BF01584082 10.1530/EJE-09-0222 10.1023/B:PITU.0000023424.72021.e2 10.20945/2359-3997000000192 10.1007/s11102-007-0030-1 10.1007/978-1-62703-616-0_7 10.1046/j.1365-2265.1997.1430983.x 10.1373/clinchem.2010.150631 10.1038/s41574-018-0058-5 10.1016/j.tem.2014.10.005 10.1053/meta.2003.50036 10.1530/EJE-11-0657 10.1210/jc.2014-2700 10.1111/j.1365-2265.2004.02064.x 10.1210/er.2002-0022 10.1007/s40618-018-0928-7 10.1210/jc.2007-1191 10.1227/NEU.0b013e31823f5c16 10.1053/meta.2002.32017 10.1517/17530059.2013.820181 10.1210/jc.2012-2477 10.1016/j.matpr.2021.01.691 10.1007/BF02604639 10.1007/s11102-017-0797-7 10.3748/wjg.14.3484 10.1016/S0889-8529(18)30204-4 10.1007/BF03345139 10.1530/EJE-14-0304 |
| ContentType | Journal Article |
| Copyright | Italian Society of Endocrinology (SIE) 2021 2021. Italian Society of Endocrinology (SIE). Italian Society of Endocrinology (SIE) 2021. |
| Copyright_xml | – notice: Italian Society of Endocrinology (SIE) 2021 – notice: 2021. Italian Society of Endocrinology (SIE). – notice: Italian Society of Endocrinology (SIE) 2021. |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM K9. NAPCQ 7X8 |
| DOI | 10.1007/s40618-021-01731-0 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Premium MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Premium MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic ProQuest Health & Medical Complete (Alumni) |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1720-8386 |
| EndPage | 987 |
| ExternalDocumentID | 35098493 10_1007_s40618_021_01731_0 |
| Genre | Journal Article |
| GroupedDBID | --- -EM .GJ 0R~ 203 4.4 406 53G 5GY 5RE 8RF 8YF 96X AACDK AAEWM AAHNG AAIAL AAJBT AAJKR AANXM AANZL AARTL AASML AATNV AATVU AAUYE AAWCG AAYIU AAYQN AAYTO AAZMS ABAKF ABDZT ABECU ABFTV ABHLI ABIPD ABJNI ABJOX ABKCH ABMQK ABPLI ABQBU ABTEG ABTKH ABTMW ABXPI ACAOD ACDTI ACGFS ACHSB ACKNC ACMLO ACOKC ACPIV ACPRK ACUDM ACZOJ ADHHG ADINQ ADJJI ADKNI ADKPE ADURQ ADYFF ADZKW AEBTG AEFQL AEGNC AEJHL AEJRE AEKMD AEMSY AENEX AEODN AEOHA AEPYU AESKC AETCA AEVLU AEXYK AFBBN AFQWF AFZKB AGAYW AGDGC AGJBK AGMZJ AGQEE AGQMX AGRTI AGWZB AGYKE AHAVH AHBYD AHIZS AHSBF AI. AIAKS AIGIU AILAN AITGF AJBLW AJRNO AJZVZ AKLTO AKMHD ALFXC ALMA_UNASSIGNED_HOLDINGS AMKLP AMXSW AMYLF AMYQR ANMIH ASPBG AUKKA AVWKF AXYYD AZFZN BGNMA CSCUP DNIVK DPUIP EBLON EBS EIOEI EJD ESBYG F5P FERAY FFXSO FIGPU FINBP FNLPD FRRFC FSGXE FYJPI GGCAI GGRSB GJIRD GQ7 GRRUI HG6 HRMNR I0C IKXTQ IMOTQ ITM IWAJR J-C JBSCW JZLTJ KOV LLZTM M4Y NPVJJ NQJWS NU0 O93 O9G O9J P2P PT4 RHV RLLFE ROL RSV SCLPG SDE SHX SISQX SJYHP SNE SNPRN SNX SOHCF SOJ SPISZ SRMVM SSLCW SSXJD STPWE TSG U9L UG4 UOJIU UTJUX UZXMN VFIZW VH1 W48 Z7U Z83 Z87 ZGI ZMTXR ZOVNA ZXP AAYXX ABBRH ABDBE ABFSG ABRTQ ACSTC AEZWR AFDZB AFHIU AFOHR AHPBZ AHWEU AIXLP ATHPR AYFIA CITATION CGR CUY CVF ECM EIF NPM K9. NAPCQ 7X8 |
| ID | FETCH-LOGICAL-c375t-d6b825daa8c6bb7b7deec7e17233f1c8559c4e3169bd7ceed016636d87e8aa893 |
| IEDL.DBID | AGYKE |
| ISSN | 1720-8386 0391-4097 |
| IngestDate | Fri Sep 05 09:17:15 EDT 2025 Tue Oct 07 06:45:51 EDT 2025 Mon Jul 21 06:04:21 EDT 2025 Wed Oct 01 02:53:11 EDT 2025 Thu Apr 24 22:57:01 EDT 2025 Fri Feb 21 02:46:43 EST 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 5 |
| Keywords | Acromegaly Oral glucose tolerance test Growth hormone suppression Growth hormone Acromegaly diagnosis |
| Language | English |
| License | 2021. Italian Society of Endocrinology (SIE). |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c375t-d6b825daa8c6bb7b7deec7e17233f1c8559c4e3169bd7ceed016636d87e8aa893 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| ORCID | 0000-0001-7550-7023 |
| PMID | 35098493 |
| PQID | 2649015547 |
| PQPubID | 2043718 |
| PageCount | 7 |
| ParticipantIDs | proquest_miscellaneous_2624200399 proquest_journals_2649015547 pubmed_primary_35098493 crossref_primary_10_1007_s40618_021_01731_0 crossref_citationtrail_10_1007_s40618_021_01731_0 springer_journals_10_1007_s40618_021_01731_0 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2022-05-01 |
| PublicationDateYYYYMMDD | 2022-05-01 |
| PublicationDate_xml | – month: 05 year: 2022 text: 2022-05-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | Cham |
| PublicationPlace_xml | – name: Cham – name: Italy – name: Heidelberg |
| PublicationSubtitle | Official Journal of Italian Society of Endocrinology (SIE) |
| PublicationTitle | Journal of endocrinological investigation |
| PublicationTitleAbbrev | J Endocrinol Invest |
| PublicationTitleAlternate | J Endocrinol Invest |
| PublicationYear | 2022 |
| Publisher | Springer International Publishing Springer Nature B.V |
| Publisher_xml | – name: Springer International Publishing – name: Springer Nature B.V |
| References | Freda, Reyes, Nuruzzaman, Sundeen, Bruce (CR13) 2003; 6 Schilbach, Bidlingmaier (CR31) 2019; 63 Bidlingmaier (CR29) 2008 Guha (CR30) 2013; 1065 Colao, Ferone, Marzullo, Lombardi (CR9) 2004; 25 Giustina, Chanson, Bronstein, Klibanski, Lamberts, Casanueva (CR16) 2010 Caputo, Ucciero, Mele, De Marchi, Magnani, Cena (CR3) 2019; 42 Rokkas, Pistiolas, Sechopoulos, Margantinis, Koukoulis (CR7) 2008; 14 Minuto, Resmini, Boschetti, Arvigo, Sormani, Giusti (CR19) 2004; 61 Freda, Post, Powell, Wardlaw (CR12) 1998; 83 Grottoli, Razzore, Gaia, Gasperi, Giusti, Colao (CR17) 2003 Ku, Hong, Kim, Kim, Lee (CR25) 2014; 171 Ronchi, Giavoli, Ferrante, Verrua, Bergamaschi, Ferrari (CR26) 2009; 161 De Marinis, Mancini, Bianchi, Gentilella, Valle, Giampietro (CR18) 2002; 51 Kim, Oh, Lee, Kim (CR14) 2012; 70 Edmonds (CR20) 1971; 1 Bidlingmaier, Strasburger (CR28) 2007; 10 Katznelson, Laws, Melmed, Molitch, Murad, Utz (CR1) 2014; 99 Molitch (CR5) 1992; 21 Rajesh Khanna, Shirisha, Kauda (CR22) 2021 Kannan, Kennedy (CR10) 2013; 7 Yamada, Fukuhara, Nishioka, Takeshita, Suzuki, Miyakawa (CR23) 2011; 165 Dekkers, Biermasz, Pereira, Romijn, Vandenbroucke (CR8) 2008; 93 Vierhapper, Heinze, Gessl, Exner, Bieglmayr (CR15) 2003; 52 Pivonello, Auriemma, Grasso, Pivonello, Simeoli, Patalano (CR6) 2017; 20 Stoffel-Wagner, Springer, Bidlingmaier, Klingmüller (CR11) 1997; 46 Melmed, Bronstein, Chanson, Klibanski, Casanueva, Wass (CR2) 2018; 14 Mazziotti, Marzullo, Doga, Aimaretti, Giustina (CR24) 2015; 26 Bouchet (CR21) 1987; 38 Drange, Fram, Herman-Bonert, Melmed (CR4) 2000; 85 Giavoli, Profka, Verrua, Ronchi, Ferrante, Bergamaschi (CR27) 2012; 97 Clemmons (CR32) 2011; 57 S Melmed (1731_CR2) 2018; 14 M Caputo (1731_CR3) 2019; 42 S Grottoli (1731_CR17) 2003 A Giustina (1731_CR16) 2010 G Mazziotti (1731_CR24) 2015; 26 MR Drange (1731_CR4) 2000; 85 A Colao (1731_CR9) 2004; 25 F Minuto (1731_CR19) 2004; 61 H Vierhapper (1731_CR15) 2003; 52 CR Ku (1731_CR25) 2014; 171 DR Clemmons (1731_CR32) 2011; 57 C Giavoli (1731_CR27) 2012; 97 M Bidlingmaier (1731_CR29) 2008 K Rajesh Khanna (1731_CR22) 2021 L De Marinis (1731_CR18) 2002; 51 L Katznelson (1731_CR1) 2014; 99 B Stoffel-Wagner (1731_CR11) 1997; 46 M Bidlingmaier (1731_CR28) 2007; 10 R Pivonello (1731_CR6) 2017; 20 CL Ronchi (1731_CR26) 2009; 161 K Schilbach (1731_CR31) 2019; 63 S Yamada (1731_CR23) 2011; 165 M Molitch (1731_CR5) 1992; 21 S Kannan (1731_CR10) 2013; 7 PU Freda (1731_CR12) 1998; 83 EH Kim (1731_CR14) 2012; 70 J Edmonds (1731_CR20) 1971; 1 PU Freda (1731_CR13) 2003; 6 N Guha (1731_CR30) 2013; 1065 OM Dekkers (1731_CR8) 2008; 93 T Rokkas (1731_CR7) 2008; 14 A Bouchet (1731_CR21) 1987; 38 |
| References_xml | – year: 2008 ident: CR29 article-title: Problems with GH assays and strategies toward standardization publication-title: Eur J Endocrinol doi: 10.1530/EJE-08-0284 – year: 2010 ident: CR16 article-title: A consensus on criteria for cure of acromegaly publication-title: J Clin Endocrinol Metabol Endocrine Soc doi: 10.1210/jc.2009-2670 – volume: 1 start-page: 127 issue: 1 year: 1971 end-page: 136 ident: CR20 article-title: Matroids and the greedy algorithm publication-title: Mathem Programm. doi: 10.1007/BF01584082 – volume: 161 start-page: 37 issue: 1 year: 2009 end-page: 42 ident: CR26 article-title: Prevalence of GH deficiency in cured acromegalic patients: Impact of different previous treatments publication-title: Eur J Endocrinol doi: 10.1530/EJE-09-0222 – volume: 6 start-page: 175 issue: 4 year: 2003 end-page: 180 ident: CR13 article-title: Basal and glucose-suppressed GH levels less than 1 μg/L in newly diagnosed acromegaly publication-title: Pituitary doi: 10.1023/B:PITU.0000023424.72021.e2 – volume: 63 start-page: 618 issue: 6 year: 2019 end-page: 629 ident: CR31 article-title: Laboratory investigations in the diagnosis and follow-up of GH-related disorders publication-title: Arch Endocrinol Metab doi: 10.20945/2359-3997000000192 – volume: 10 start-page: 115 issue: 2 year: 2007 end-page: 119 ident: CR28 article-title: Growth hormone assays: Current methodologies and their limitations publication-title: Pituitary doi: 10.1007/s11102-007-0030-1 – volume: 83 start-page: 3808 issue: 11 year: 1998 end-page: 3816 ident: CR12 article-title: Evaluation of disease status with sensitive measures of growth hormone secretion in 60 postoperative patients with acromegaly 1 publication-title: J Clin Endocrinol Metab – volume: 1065 start-page: 117 year: 2013 end-page: 128 ident: CR30 article-title: Assays for GH, IGF-I, and IGF binding protein-3 publication-title: Methods Mol Biol doi: 10.1007/978-1-62703-616-0_7 – volume: 46 start-page: 531 issue: 5 year: 1997 end-page: 537 ident: CR11 article-title: A comparison of different methods for diagnosing acromegaly publication-title: Clin Endocrinol (Oxf) doi: 10.1046/j.1365-2265.1997.1430983.x – volume: 57 start-page: 555 issue: 4 year: 2011 end-page: 559 ident: CR32 article-title: Consensus statement on the standardization and evaluation of growth hormone and insulin-like growth factor assays publication-title: Clin Chem doi: 10.1373/clinchem.2010.150631 – volume: 14 start-page: 552 issue: 9 year: 2018 end-page: 561 ident: CR2 article-title: A consensus statement on acromegaly therapeutic outcomes publication-title: Nat Rev Endocrinol doi: 10.1038/s41574-018-0058-5 – volume: 26 start-page: 11 issue: 1 year: 2015 end-page: 21 ident: CR24 article-title: Growth hormone deficiency in treated acromegaly publication-title: Trends Endocrinol Metab doi: 10.1016/j.tem.2014.10.005 – volume: 52 start-page: 181 issue: 2 year: 2003 end-page: 185 ident: CR15 article-title: Use of the oral glucose tolerance test to define remission in acromegaly publication-title: Metabolism doi: 10.1053/meta.2003.50036 – volume: 165 start-page: 873 issue: 6 year: 2011 end-page: 879 ident: CR23 article-title: GH deficiency in patients after cure of acromegaly by surgery alone publication-title: Eur J Endocrinol doi: 10.1530/EJE-11-0657 – volume: 99 start-page: 3933 issue: 11 year: 2014 end-page: 3951 ident: CR1 article-title: Acromegaly: An endocrine society clinical practice guideline publication-title: J Clin Endocrinol Metab doi: 10.1210/jc.2014-2700 – volume: 61 start-page: 138 issue: 1 year: 2004 end-page: 144 ident: CR19 article-title: Assessment of disease activity in acromegaly by means of a single blood sample: Comparison of the 120th minute postglucose value with spontaneous GH secretion and with the IGF system publication-title: Clin Endocrinol (Oxf) doi: 10.1111/j.1365-2265.2004.02064.x – volume: 25 start-page: 102 issue: 1 year: 2004 end-page: 152 ident: CR9 article-title: Systemic complications of acromegaly: epidemiology, pathogenesis, and management publication-title: Endocr Rev doi: 10.1210/er.2002-0022 – volume: 42 start-page: 397 issue: 4 year: 2019 end-page: 402 ident: CR3 article-title: Use of administrative health databases to estimate incidence and prevalence of acromegaly in Piedmont Region, Italy publication-title: J Endocrinol Invest doi: 10.1007/s40618-018-0928-7 – volume: 93 start-page: 61 issue: 1 year: 2008 end-page: 67 ident: CR8 article-title: Mortality in acromegaly: a metaanalysis publication-title: J Clin Endocrinol Metab doi: 10.1210/jc.2007-1191 – volume: 70 start-page: 1106 issue: 5 year: 2012 end-page: 1112 ident: CR14 article-title: Predicting long-term remission by measuring immediate postoperative growth hormone levels and oral glucose tolerance test in acromegaly publication-title: Neurosurgery doi: 10.1227/NEU.0b013e31823f5c16 – volume: 51 start-page: 616 issue: 5 year: 2002 end-page: 621 ident: CR18 article-title: Preoperative growth hormone response to thyrotropin-releasing hormone and oral glucose tolerance test in acromegaly: A retrospective evaluation of 50 patients publication-title: Metabolism doi: 10.1053/meta.2002.32017 – volume: 7 start-page: 443 issue: 5 year: 2013 end-page: 453 ident: CR10 article-title: Diagnosis of acromegaly: State of the art publication-title: Expert Opin Med Diagn doi: 10.1517/17530059.2013.820181 – volume: 85 start-page: 168 issue: 1 year: 2000 end-page: 174 ident: CR4 article-title: Pituitary tumor registry: a novel clinical resource 1 publication-title: J Clin Endocrinol Metab – volume: 97 start-page: 3983 issue: 11 year: 2012 end-page: 3988 ident: CR27 article-title: GH replacement improves quality of life and metabolic parameters in cured acromegalic patients with growth hormone deficiency publication-title: J Clin Endocrinol Metab doi: 10.1210/jc.2012-2477 – year: 2021 ident: CR22 article-title: A review of approaches and associated dimensions with greedy method for research implementations publication-title: Mater Today Proc doi: 10.1016/j.matpr.2021.01.691 – volume: 38 start-page: 147 issue: 2 year: 1987 end-page: 159 ident: CR21 article-title: Greedy algorithm and symmetric matroids publication-title: Mathem Programm doi: 10.1007/BF02604639 – volume: 20 start-page: 46 issue: 1 year: 2017 end-page: 62 ident: CR6 article-title: Complications of acromegaly: cardiovascular, respiratory and metabolic comorbidities publication-title: Pituitary doi: 10.1007/s11102-017-0797-7 – volume: 14 start-page: 3484 issue: 22 year: 2008 end-page: 3489 ident: CR7 article-title: Risk of colorectal neoplasm in patients with acromegaly: a meta-analysis publication-title: World J Gastroenterol doi: 10.3748/wjg.14.3484 – volume: 21 start-page: 597 issue: 3 year: 1992 end-page: 614 ident: CR5 article-title: Clinical manifestations of acromegaly publication-title: Endocrinol Metab Clin North Am doi: 10.1016/S0889-8529(18)30204-4 – year: 2003 ident: CR17 article-title: Three-hour spontaneous GH secretion profile is as reliable as oral glucose tolerance test for the diagnosis of acromegaly publication-title: J Endocrinol Invest doi: 10.1007/BF03345139 – volume: 171 start-page: 379 issue: 3 year: 2014 end-page: 387 ident: CR25 article-title: Clinical predictors of GH deficiency in surgically cured acromegalic patients publication-title: Eur J Endocrinol doi: 10.1530/EJE-14-0304 – volume: 46 start-page: 531 issue: 5 year: 1997 ident: 1731_CR11 publication-title: Clin Endocrinol (Oxf) doi: 10.1046/j.1365-2265.1997.1430983.x – volume: 14 start-page: 552 issue: 9 year: 2018 ident: 1731_CR2 publication-title: Nat Rev Endocrinol doi: 10.1038/s41574-018-0058-5 – volume: 171 start-page: 379 issue: 3 year: 2014 ident: 1731_CR25 publication-title: Eur J Endocrinol doi: 10.1530/EJE-14-0304 – volume: 161 start-page: 37 issue: 1 year: 2009 ident: 1731_CR26 publication-title: Eur J Endocrinol doi: 10.1530/EJE-09-0222 – volume: 51 start-page: 616 issue: 5 year: 2002 ident: 1731_CR18 publication-title: Metabolism doi: 10.1053/meta.2002.32017 – volume: 1065 start-page: 117 year: 2013 ident: 1731_CR30 publication-title: Methods Mol Biol doi: 10.1007/978-1-62703-616-0_7 – volume: 10 start-page: 115 issue: 2 year: 2007 ident: 1731_CR28 publication-title: Pituitary doi: 10.1007/s11102-007-0030-1 – volume: 38 start-page: 147 issue: 2 year: 1987 ident: 1731_CR21 publication-title: Mathem Programm doi: 10.1007/BF02604639 – volume: 93 start-page: 61 issue: 1 year: 2008 ident: 1731_CR8 publication-title: J Clin Endocrinol Metab doi: 10.1210/jc.2007-1191 – volume: 85 start-page: 168 issue: 1 year: 2000 ident: 1731_CR4 publication-title: J Clin Endocrinol Metab – volume: 6 start-page: 175 issue: 4 year: 2003 ident: 1731_CR13 publication-title: Pituitary doi: 10.1023/B:PITU.0000023424.72021.e2 – year: 2010 ident: 1731_CR16 publication-title: J Clin Endocrinol Metabol Endocrine Soc doi: 10.1210/jc.2009-2670 – year: 2021 ident: 1731_CR22 publication-title: Mater Today Proc doi: 10.1016/j.matpr.2021.01.691 – volume: 52 start-page: 181 issue: 2 year: 2003 ident: 1731_CR15 publication-title: Metabolism doi: 10.1053/meta.2003.50036 – volume: 25 start-page: 102 issue: 1 year: 2004 ident: 1731_CR9 publication-title: Endocr Rev doi: 10.1210/er.2002-0022 – volume: 83 start-page: 3808 issue: 11 year: 1998 ident: 1731_CR12 publication-title: J Clin Endocrinol Metab – volume: 1 start-page: 127 issue: 1 year: 1971 ident: 1731_CR20 publication-title: Mathem Programm. doi: 10.1007/BF01584082 – year: 2008 ident: 1731_CR29 publication-title: Eur J Endocrinol doi: 10.1530/EJE-08-0284 – year: 2003 ident: 1731_CR17 publication-title: J Endocrinol Invest doi: 10.1007/BF03345139 – volume: 63 start-page: 618 issue: 6 year: 2019 ident: 1731_CR31 publication-title: Arch Endocrinol Metab doi: 10.20945/2359-3997000000192 – volume: 61 start-page: 138 issue: 1 year: 2004 ident: 1731_CR19 publication-title: Clin Endocrinol (Oxf) doi: 10.1111/j.1365-2265.2004.02064.x – volume: 57 start-page: 555 issue: 4 year: 2011 ident: 1731_CR32 publication-title: Clin Chem doi: 10.1373/clinchem.2010.150631 – volume: 20 start-page: 46 issue: 1 year: 2017 ident: 1731_CR6 publication-title: Pituitary doi: 10.1007/s11102-017-0797-7 – volume: 70 start-page: 1106 issue: 5 year: 2012 ident: 1731_CR14 publication-title: Neurosurgery doi: 10.1227/NEU.0b013e31823f5c16 – volume: 7 start-page: 443 issue: 5 year: 2013 ident: 1731_CR10 publication-title: Expert Opin Med Diagn doi: 10.1517/17530059.2013.820181 – volume: 21 start-page: 597 issue: 3 year: 1992 ident: 1731_CR5 publication-title: Endocrinol Metab Clin North Am doi: 10.1016/S0889-8529(18)30204-4 – volume: 26 start-page: 11 issue: 1 year: 2015 ident: 1731_CR24 publication-title: Trends Endocrinol Metab doi: 10.1016/j.tem.2014.10.005 – volume: 14 start-page: 3484 issue: 22 year: 2008 ident: 1731_CR7 publication-title: World J Gastroenterol doi: 10.3748/wjg.14.3484 – volume: 97 start-page: 3983 issue: 11 year: 2012 ident: 1731_CR27 publication-title: J Clin Endocrinol Metab doi: 10.1210/jc.2012-2477 – volume: 165 start-page: 873 issue: 6 year: 2011 ident: 1731_CR23 publication-title: Eur J Endocrinol doi: 10.1530/EJE-11-0657 – volume: 99 start-page: 3933 issue: 11 year: 2014 ident: 1731_CR1 publication-title: J Clin Endocrinol Metab doi: 10.1210/jc.2014-2700 – volume: 42 start-page: 397 issue: 4 year: 2019 ident: 1731_CR3 publication-title: J Endocrinol Invest doi: 10.1007/s40618-018-0928-7 |
| SSID | ssj0037387 |
| Score | 2.3299513 |
| Snippet | Background
In patients with suspected acromegaly, evaluation of IGF-I is recommended as first-line test, while the assessment of GH-nadir during oral glucose... In patients with suspected acromegaly, evaluation of IGF-I is recommended as first-line test, while the assessment of GH-nadir during oral glucose tolerance... BackgroundIn patients with suspected acromegaly, evaluation of IGF-I is recommended as first-line test, while the assessment of GH-nadir during oral glucose... |
| SourceID | proquest pubmed crossref springer |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 981 |
| SubjectTerms | Accuracy Acromegaly Acromegaly - diagnosis Blood Specimen Collection Cohort Studies Endocrinology Glucose tolerance Glucose Tolerance Test Human Growth Hormone Humans Insulin-Like Growth Factor I Internal Medicine Medicine Medicine & Public Health Metabolic Diseases Original Article |
| Title | Optimal timing of blood samplings to detect GH inhibition during oral glucose tolerance test |
| URI | https://link.springer.com/article/10.1007/s40618-021-01731-0 https://www.ncbi.nlm.nih.gov/pubmed/35098493 https://www.proquest.com/docview/2649015547 https://www.proquest.com/docview/2624200399 |
| Volume | 45 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVLSH databaseName: SpringerLink Journals customDbUrl: mediaType: online eissn: 1720-8386 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0037387 issn: 1720-8386 databaseCode: AFBBN dateStart: 19970101 isFulltext: true providerName: Library Specific Holdings – providerCode: PRVAVX databaseName: SpringerLINK - Czech Republic Consortium customDbUrl: eissn: 1720-8386 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0037387 issn: 1720-8386 databaseCode: AGYKE dateStart: 19970101 isFulltext: true titleUrlDefault: http://link.springer.com providerName: Springer Nature |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3dS-QwEB90hcMXv_V6ehLBN63stmnSPqq4LoreiwseCCVfu4peV267L_fX30ybVk5PwZdS6KRNM5PML8xvJgD7GbpYEXEVKqW7IRcjHaZWqjBSKomEogp8lOB8dS0GQ35xm9z6pLBpw3ZvQpLVSt0mu5HrSUOiFKAVxXidh4Wq3lYHFo7Pf16eNSswFeuRPkHm_y3_dUJvkOWbqGjlbPrLMGy6WXNMHo9mpT4yf15VcPzsf6zAkkef7Lg2l1WYc8UafLny8fV1uPuBK8gvlCjpsK8xm4xYxWxnU0XM82I8ZeWEWUeRB3Y-YA_F_YOuSF-szndklPDPPA8eZZ8cHdyBd_jjGzDsn92cDkJ__kJoYpmUoRUa949WqdQIraWW1jkjHUIeVGDPpLgZMdzFPZFpK8nZInwUsbCpdCk2yuJN6BSTwn0FFnFLlcG63ZFJuY0iHWc84RE6Cp6YnhgF0GsUkhtfnJzOyHjK27LK1bDlOGx5NWx5N4CDts1zXZrjQ-mdRs-5n6bTHNEg4aGEywD22sc4wShqogo3mZEMohhKYc4C2Krto_1cjHAr5VkcwGGj65eXv9-Xb58T34bFiJIuKprlDnTK3zP3HaFQqXfR8vsnJ9e7fgb8Ba-O_3o |
| linkProvider | Springer Nature |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3db9MwED9BJ8Fe-BhsBAbzJN4gU-s4dvI4TVvL2o6XVhoSUuSvjomRIpq-8NdzlziZtgHSXqJIOSeOz_b9rLvfHcD7HE2s5ELHWpt-LOTCxJlTOuZap1xqysBHBOfpmRzNxel5eh5IYas22r11SdY7dUd2I9OTxRRSgLMowetD2BB4QOE92DgcfhkftzswJetRgSDz95Y3jdAdZHnHK1obm5OnMG-72cSYfD9YV-bA_r6VwfG-__EMngT0yQ6b6fIcHvhyCx5Ng3_9BXz9jDvID5SoqNjXBVsuWB3ZzlaaIs_LixWrlsx58jyw4Yhdlt8uTR30xRq-IyPCPwtx8Ch75alwB97hj7-E-cnx7GgUh_oLsU1UWsVOGjw_Oq0zK41RRjnvrfIIeVCBA5vhYcQKnwxkbpwiY4vwUSbSZcpn2ChPtqFXLkv_ChgXjjKD9fsLmwnHuUlykQqOhkKkdiAXEQxahRQ2JCenGhlXRZdWuR62AoetqIet6EfwoWvzs0nN8V_p3VbPRVimqwLRIOGhVKgI9rvHuMDIa6JLv1yTDKIYojDnEew086P7XIJwKxN5EsHHVtfXL_93X17fT3wPHo9m00kx-XQ2fgObnAgYdcjlLvSqX2v_FmFRZd6FVfAHoZUA7A |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1ZT9wwEB5RkFBfuEohXDVS30pgN3Hs5BEBy7acD0WiUqXIVwABWcRmX_j1zOTibKWqL1GkjBNnxvZ81sx8BviaoIsVAVe-Urrjc5FpP7ZS-YFSUSAUMfBRgfPRseif8R_n0fmzKv4y270JSVY1DcTSlBdbdzbbagvfyA3FPqUX4IgK8foBJnBrInGkT2zv_zrYa1ZjIu6RdbHM-y1fOqQ3KPNNhLR0PL1pUE2Xq3yT681RoTfNwys2x__5pxmYqlEp266G0SyMuXwOJo_quPsn-H2CK8stShR0CNgFG2SszHhnQ0UZ6fnFkBUDZh1FJNh-n13ll1e6TAZjVR0kIyIAVufHo-yNowM98A6VMA9nvb2fO32_PpfBN6GMCt8KjftKq1RshNZSS-uckQ6hEBq2a2LcpBjuwq5ItJXkhBFWilDYWLoYGyXhZxjPB7lbBBZwS4xhnU5mYm6DQIcJj3iADoRHpisyD7qNcVJTk5bT2Rk3aUu3XKotRbWlpdrSjgff2jZ3FWXHX6VXGpun9fQdpogSCSdFXHqw3j7GiUfRFJW7wYhkEN1QaXPiwUI1VtrPhQjDYp6EHmw0dn96-Z_7svRv4l9g8nS3lx5-Pz5Yho8B1WVQqk20AuPF_citIloq9Fo9IR4BeIAJ0Q |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Optimal+timing+of+blood+samplings+to+detect+GH+inhibition+during+oral+glucose+tolerance+test&rft.jtitle=Journal+of+endocrinological+investigation&rft.au=Bioletto%2C+F&rft.au=Prencipe%2C+N&rft.au=Berton%2C+A+M&rft.au=Bona%2C+C&rft.date=2022-05-01&rft.pub=Springer+Nature+B.V&rft.issn=0391-4097&rft.eissn=1720-8386&rft.volume=45&rft.issue=5&rft.spage=981&rft.epage=987&rft_id=info:doi/10.1007%2Fs40618-021-01731-0&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1720-8386&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1720-8386&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1720-8386&client=summon |